Journey Medical Sees Emrosi Joining Plan Covering 25 Million Lives in 2027

Journey Medical expects Emrosi to join a national plan covering more than 25 million lives in 2027, a move management expects to shift prescriptions toward reimbursed sales.

Emrosi generated $9 million in third-quarter sales, with about 40,000 prescriptions and more than 5,000 unique prescribers. Emrosi currently has high-quality access for 40% of commercial lives. Journey Medical also posted positive adjusted EBITDA for a second consecutive quarter.

Changes to copay bridging contributed to prescription volatility. Management said first-quarter deductible resets may affect average selling price progression. Journey Medical is weighing 2027 guidance and has expressed caution about issuing it early in the year.